Pasireotide, an IGF-I action inhibitor, prevents growth hormone and estradiol-induced mammary hyperplasia. (Q51539178)

6 April 2018

title

Pasireotide, an IGF-I action inhibitor, prevents growth hormone and estradiol-induced mammary hyperplasia. (English)

1 reference

6 April 2018

author name string

David L Kleinberg

series ordinal

1

1 reference

6 April 2018

Pietro Ameri

series ordinal

2

1 reference

6 April 2018

Baljit Singh

series ordinal

3

1 reference

6 April 2018

publication date

1 March 2011

1 reference

6 April 2018

published in

Pituitary

1 reference

6 April 2018

volume

14

1 reference

6 April 2018

issue

1

1 reference

6 April 2018

page(s)

44-52

1 reference

6 April 2018

Benign breast disease and the risk of breast cancer

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0257-0

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0257-0

Intact and amino-terminally shortened forms of insulin-like growth factor I induce mammary gland differentiation and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0257-0

Progesterone stimulates mammary gland ductal morphogenesis by synergizing with and enhancing insulin-like growth factor-I action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0257-0

SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0257-0

Treatment with a somatostatin analog decreases pancreatic B-cell and whole body sensitivity to glucose.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0257-0

Prognostic significance of benign proliferative breast disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0257-0

Cell proliferation, apoptosis, and expression of cyclin D1 and cyclin E as potential biomarkers in tamoxifen-treated mammary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0257-0

Tamoxifen resistance and Her2/neu expression in an aged, irradiated rat breast carcinoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0257-0

Growth factor regulation of cell cycle progression in mammary epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0257-0

SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0257-0

A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0257-0

Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0257-0

Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0257-0

Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0257-0

The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0257-0

A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0257-0

Rapid induction of IGF-IR signaling in normal and tumor tissue following intravenous injection of IGF-I in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0257-0

Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0257-0

BMS-536924 reverses IGF-IR-induced transformation of mammary epithelial cells and causes growth inhibition and polarization of MCF7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0257-0

The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0257-0

Non-lactogenic effects of growth hormone on growth and insulin-like growth factor-I messenger ribonucleic acid of rat mammary gland

21 January 2018

1 reference

12 December 2020

Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development

1 reference

12 December 2020

Risk factors for breast cancer in women with proliferative breast disease

1 reference

12 December 2020

Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor

1 reference

12 December 2020

Evidence that the growth hormone receptor mediates differentiation and development of the mammary gland

1 reference

12 December 2020

Targeted disruption of the IGF-I receptor gene decreases cellular proliferation in mammary terminal end buds

1 reference

12 December 2020

Regulation of cell apoptosis by insulin-like growth factor I.

1 reference

12 December 2020

Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid

1 reference

12 December 2020

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer

1 reference

12 December 2020

Quality of life and tamoxifen in a breast cancer prevention trial: a summary of findings from the NSABP P-1 study. National Surgical Adjuvant Breast and Bowel Project

1 reference

12 December 2020

Evidence that insulin-like growth factor I and growth hormone are required for prostate gland development

1 reference

12 December 2020

Responsiveness to somatostatin analog treatment and potentials of novel somatostatin analog.

1 reference

12 December 2020

Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells

1 reference

12 December 2020

Effect of ovariectomy on hormone receptors and growth of N-nitrosomethylurea-induced mammary tumors in the rat

1 reference

12 December 2020

Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3

1 reference

12 December 2020

10.1007/S11102-010-0257-0

Identifiers

DOI

1 reference

6 April 2018

release_z5wfqso6ibgjrnztg3la3e335q

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/z5wfqso6ibgjrnztg3la3e335q

24 November 2022

mapped directly with Wikidata item

1 reference

6 April 2018